SpectraWAVE, Inc. on LinkedIn: Join us next week in Long Beach for SCAI 2024! Come by booth 411 for a… (2024)

📢Is it time to consider treating non-flow limiting plaques at increased risk of MACE?PREVENT trial results published recently in The Lancet demonstrated improved clinical outcomes at 2 years when performing preventative PCI on high-risk plaques vs. medical therapy alone. Preventative PCI on non-flow limiting plaques identified by intravascular imaging resulted in:⬇️ Target Vessel Failure (TVF) at 2 years and 7 years⬇️ Composite of death from any cause, any MI, and any revascularization at 2 yearsLearn more about how SpectraWAVE’s HyperVue Imaging System can identify patients and plaques at increased risk of major adverse cardiac events at www.spectrawave.comRead full publication here: https://lnkd.in/eURyEZKK

32

Thrilled to share our CEO Eman Namati presenting SpectraWAVE’s HyperVue Imaging System and the unique value of our #DeepOCT+NIRS technology for simple, fast and effective coronary stent planning and optimization. #LSIUSA24

108

3 Comments

Our CEO Eman Namati will be presenting today at #LSIUSA24, Medtech's premier partnering event. Join him in Track 1 at 5 PM this evening to learn more about SpectraWAVE!#LSIAlumni #medtech

54

📣 New Publication out now in JSCAI highlighting clinical experience and unique value of the HyperVue Imaging System, SpectraWAVE’s intravascular imaging platform!The publication showcases DeepOCT+NIRS imaging in various plaque morphologies, and head-to-head image comparisons to other commercial products. Congratulations to all the authors! Read the full publication here: https://lnkd.in/ekrNK6QX

74

2 Comments

❗ A landmark meta-analysis published in The Lancet featuring data from 15,964 patients in 22 trials, demonstrates reduction of cardiac death, MI, ST, TLF, and all cause death, when using intravascular imaging-guided PCI vs angio alone.Compared to angio-guided PCI, utilizing intravascular imaging (OCT or IVUS) resulted in: 29% ⬇ in Target Lesion Failure (TLF) 45% ⬇ in cardiac death 25% ⬇ in all-cause mortality 17% ⬇ in Myocardial Infarction (MI) 48% ⬇ in the risk of definite or probable stent thrombosis (ST)This data is significant for patients and physicians who care for them. The HyperVue Imaging System was designed with both patients and physicians in mind, combining next generation DeepOCT + NIRS images with simplified workflows for confident clinical decision making.To learn more about our product, please visit: www.spectrawave.comhttps://lnkd.in/egacphv6

116

SpectraWAVE is excited to announce two new additions to theBoardof Directors – David Neustaedter of Deerfield Management, and Ramin Mousavi of CathWorks.At this pivotal point in the company’s tenure, as we commercialize the HyperVue Imaging System in the United States, we look forward to leveraging the wealth of venture and commercial MedTech experience from each of these incredible leaders.

71

4 Comments

Join Dr. Ziad Ali for a presentation on the HyperVue Imaging System tomorrow 10/26 at #TCT2023 to learn more about SpectraWAVE’s next generation intravascular imaging platform! #DeepOCT

37

It’s time for #TCT2023! Come by Booth 2237 to learn more about the future of intravascular imaging with the HyperVue Imaging System! #ImageWithoutCompromise #DeepOCT

42